These results suggest that combined inhibition of kinases and anti-apoptotic proteins targets MLL-ALL cells and therefore this study identified a new potential drug-treatment strategy for infant MLL-ALL patients. This evidence concerns the gene KMT2A and acute lymphoblastic leukemia.